Detalhe da pesquisa
1.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
2.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
3.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Nat Med
; 27(11): 2032-2040, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588689
4.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615860
5.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335322
6.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335323
7.
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(6): 1113, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958800
8.
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(6): 1116, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021278